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Background: The efﬁcacy of the smoking-cessation
agent varenicline has been reported in Asian smokers;
however, few studies have investigated factors that
contribute to lapse and relapse.
Objective: This post hoc analysis aimed to identify
predictors of smoking lapse and relapse.
Methods: This was a post-hoc analysis based on a
double-blind, placebo-controlled, randomized, paral-
lel-group study in which Japanese smokers (aged 20–
75 years) who smoked ≥10 cigarettes/day and were
motivated to quit were randomized to receive vareni-
cline (0.25 mg twice daily [BID], 0.5 mg BID, 1 mg
BID) or placebo for 12 weeks followed by a 40-week
non-treatment follow-up. For inclusion in this analy-
sis, participants must have been nicotine dependent
(Tobacco Dependence Screener score Z5) and must
have successfully quit smoking continuously for 4
weeks (weeks 9–12). Lapse was deﬁned by answering
yes to Z1 question in the Nicotine Use Inventory.
Relapse was deﬁned by participants having smoked
for Z7 days during follow-up measured by the
Nicotine Use Inventory.
Results: Of the 619 randomized individuals, 515
had a Tobacco Dependence Screener score ofZ5, and
277 quit smoking continuously from weeks 9 to 12.
Approximately 75% were male, with a mean (SD)
BMI of 23.0 (3.0) kg/m2. Maximum length of
continuous abstinence (CA) during treatment and
age (both P o 0.0001) were signiﬁcant predictors of
lapse. Maximum CA (Po 0.0001), age (P ¼ 0.0002),
Minnesota Nicotine Withdrawal Scale (MNWS) score
for urge to smoke (P ¼ 0.0019), and having madeZ1
serious quit attempt (P ¼ 0.0063) were signiﬁcant
predictors of relapse. For participants with a918maximum CA of 4 to 6 weeks versus those with a
maximum CA of 10 to 11 weeks, the ORs for lapse
and relapse were 4.649 (95% CI, 2.071–10.434) and
3.337 (95% CI, 1.538–7.239), respectively. In partic-
ipants aged 21–34 years versus those aged 47–
72 years, the ORs for lapse and relapse were 3.453
(95% CI 1.851, 6.441) and 3.442 (95% CI 1.795,
6.597), respectively. Participants with a MNWS
urge to smoke score of 2 to 4 versus 0 had an
OR for relapse of 3.175 (95% CI, 1.166–8.644).
Participants having made Z1 versus no serious quit
attempts had an OR for relapse of 2.108 (95% CI,
1.168–3.805).
Conclusion: Shorter maximum CA and younger
age at quit attempt were associated with increased
risk of lapse and relapse. Higher MNWS urge to
smoke score and having made Z1 serious quit
attempt were associated with increased relapse risk.
ClinicalTrials.gov identiﬁer: NCT00139750. (Clin
Ther. 2014;36:918–927) & 2014 The Authors.
Published by Elsevier HS Journals, Inc.
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Varenicline tartrate is a selective α4β2-nicotinic acetyl-
choline receptor partial agonist that is approvedVolume 36 Number 6
M. Nakamura et al.worldwide as a smoking cessation aid at a dose of 1 mg
BID for 12 weeks starting with a 1-week up-titration.1
The efﬁcacy of varenicline as a smoking cessation aid
has been reported in a number of studies. Results from
2 double-blind, randomized, placebo-controlled studies
conducted in the United States2,3 have reported that
smoking cessation success with varenicline is signiﬁ-
cantly better compared with other smoking cessation
aids (eg, bupropion sustained-release tablets) or pla-
cebo. A Cochrane meta-analysis of 12,223 participants
in 15 studies, 8100 of whom used varenicline, revealed
that individuals who had received varenicline were
2.3 times more likely to quit at 6 months compared
with those who had received placebo.4
A number of clinical studies have reported the efﬁcacy
of varenicline in Asian smokers.5–8 Equivalence of efﬁ-
cacy and tolerability between Japanese and US smokers
has been described in a study of 618 Japanese smokers.5
This study reported a complete abstinence rate at weeks 9
to 12 of 65.4% for varenicline, which compared well
with the 44% rate reported in the US studies.2,3
Although the efﬁcacy of pharmacologic and behav-
ioral treatment for smoking cessation is well established,
these methods are not always used in quit attempts. It
has been reported that 80% of smokers who attempt to
quit without assistance relapse within the ﬁrst month of
abstinence, and only 3% to 5% continue to be abstinent
at 6 months.9,10 Results from the US Centers for Disease
Control and Prevention 2010 National Health Interview
Survey revealed that although 52.4% of smokers had
made a quit attempt in the past year, only 6.2% had
successfully quit within the same time frame.11 Results of
a Cochrane review concluded that there is insufﬁcient
evidence to support a role of behavioral therapy or
extended treatment with bupropion in preventing relapse
to smoking. However, the report suggested that extended
treatment with varenicline may prevent relapse.12
Furthermore, the results of a study investigating the use
of 12 weeks of maintenance therapy in smokers who
achieved abstinence for at least 7 consecutive days at the
end of standard varenicline treatment conﬁrmed that
individuals who received maintenance treatment had
signiﬁcantly greater continuous abstinence during
weeks 13 to 24 (70.5% vs 49.6%; odds ratio [OR],
2.48; 95% CI, 1.95–3.16; P o 0.001) and weeks 13 to
52 (43.6% vs 36.9%; OR, 1.34; 95% CI, 1.06–1.69;
P ¼ 0.02) compared with those who received placebo.13
The focus of health care professionals in treating
tobacco dependence is now directed at reducing theJune 2014number of patients who relapse after initially success-
fully quitting smoking. However, to date few studies
have investigated the factors that contribute to re-
lapse, and comparison of factors in Japanese smokers
versus those from other countries has not been
conducted. In a post hoc analysis of 626 smokers
from 2 varenicline studies conducted in the United
States, predictors of relapse from week 13 (end of
treatment) to week 52 (1-year follow-up) were as-
sessed for treatment-responding participants who
achieved the primary efﬁcacy end point of 4-week
continuous abstinence during weeks 9 to 12. The
results revealed that those who did not initiate con-
tinuous abstinence until the ﬁnal 4 weeks of the
treatment period were almost 5 times more likely to
relapse (OR, 4.92; 95% CI, 2.77–8.97; P o 0.001)
compared with those who initiated continuous absti-
nence at the end of week 1.14 Another study
conducted to assess whether smokers who achieved
abstinence later in the original course of treatment
would beneﬁt from receiving an extended course of
varenicline15 conﬁrmed that the 12-month quit suc-
cess rates decreased with increasing delay in initial
quitting, with quit rates of 54.9% for those quitting at
week 1 of open-label treatment and 5.7% for those
quitting at week 11.
This post hoc analysis was conducted to identify
predictors of smoking lapse or relapse during the
nontreatment follow-up period based on a double-
blind, placebo-controlled, randomized, parallel-group
study (ClinicalTrials.gov identiﬁer: NCT00139750),5
which was initially conducted to assess the efﬁcacy
and tolerability of varenicline in Japanese smokers.
Currently, it is not clear whether research con-
ducted on smoking cessation with Western individuals
also applies to Japanese individuals. Although there
are no signiﬁcant differences in the metabolism and
efﬁcacy of varenicline in Japanese and Western indi-
viduals,8 relapse in Japanese smokers may be
inﬂuenced by other factors. In Japan, unlike in many
westernized countries, smoke-free environments are
not mandated with penalties by law in indoor public
places, in workplaces, or on public transport, and
there are no legal restrictions on advertising. Tobacco
is also relatively less expensive in Japan compared
with many Western countries. In addition, there may
be differences in the metabolism of nicotine, the
severity of nicotine dependence, and other problems
related to smoking cessation, depending on race.919
Clinical TherapeuticsThis investigation was conducted to identify factors
that could contribute to smoking relapse in Japanese
individuals. It focused on identifying predictors and
characteristics of smoking relapse, such as the use of a
smoking cessation aid and a longer period of support
during follow-up, which may help provide an effective
strategy to prevent future relapse.
PATIENTS AND METHODS
Study Design
This was a post hoc analysis based on a double-
blind, placebo-controlled, randomized, parallel-group
study, which has been previously reported.5 A total of
619 Japanese smokers aged 20 to 75 years, who
smoked at least 10 cigarettes per day and were
motivated to quit smoking (indicated in the
informed consent form), were randomized to receive
varenicline or placebo. The number of days of
cigarette smoking since the previous contact was
checked at each visit or at each telephone contact
during the nontreatment follow-up period or at the
early termination visit if individuals discontinued the
study early during the follow-up phase.
Objectives and Definitions
The primary objective of this analysis was to
identify predictors of smoking lapse and relapse
during the nontreatment follow-up period among
individuals who reported being continuously abstinent
during the last 4 weeks of the treatment period. The
secondary objective was to investigate the time from
week 13 to smoking relapse for individuals who
reported being continuously abstinent during the last
4 weeks of the treatment period, stratiﬁed by levels of
a predictor. Lapse was deﬁned by having an exhaled
carbon monoxide measurement of410 ppm (at clinic
visits) during the nontreatment period (ie, from
week 13 through week 52) or answering yes to at
least one of the questions about smoking in the
Nicotine Use Inventory (NUI): “Has the subject
smoked any cigarettes (even a puff) since the last
contact?” or “Has the subject used any other tobacco
products since the last contact?” Relapse was deﬁned
by an individual having smoked for Z7 days during
the nontreatment follow-up period as measured by the
NUI. Time to lapse or relapse was deﬁned as the time
(in weeks) from the beginning of the nontreatment
follow-up period (ie, week 13) to the ﬁrst visit when
the individual’s lapse or relapse was observed. Those920who didn’t lapse or relapse were censored at week 52.
For individuals who discontinued follow-up visits
before lapsing, time to lapse or relapse was deﬁned
as the time from week 13 to the week corresponding
to the ﬁrst missing visit that occurred after the date of
discontinuation.
Participants
Participants were Japanese smokers (aged 20–75
years) who had participated in an earlier smoking
cessation study investigating varenicline5; had been
diagnosed as being nicotine dependent with a score of
Z5 (range, 0–10) on the Tobacco Dependence
Screener (TDS),16 which deﬁnes the criteria used to
determine which smokers are permitted access to the
smoking cessation treatment service that is reimbursed
by public health insurance in Japan; and had
successfully quit smoking continuously for 4 weeks
from weeks 9 to 12. Individuals were excluded if they
had signiﬁcant cardiovascular disease, uncontrolled
hypertension, severe chronic obstructive pulmonary
disease, or a history of cancer. Individuals who had
quit smoking continuously for 4 weeks from weeks 9
to 12 of the smoking cessation study were included in
the analysis for the primary and secondary objectives.
Predictors of Relapse
Potential predictors of relapse included age, sex,
body mass index (BMI), age at onset of smoking,
number of cigarettes smoked per day, longest absti-
nence in previous year, living with a smoker, frequent
contact with a smoker, number of serious quit
attempts before study entry, pack-years smoked, base-
line Fagerström Test for Nicotine Dependence score,
baseline serum cotinine level, baseline weekly alcohol
consumption, all domains of the Minnesota Nicotine
Withdrawal Scale (MNWS; negative affect, insomnia,
urge to smoke, restlessness, and increased appetite) at
week 12, maximum length of continuous abstinence
(CA) during the treatment phase, and quit pattern,
deﬁned as whether an individual could initiate absti-
nence on or before the target quit date.
Statistical Analysis
Model building was based on a logistic regression
model with forward selection, backward elimination,
and stepwise selection used to select potential predictors
of lapse and relapse.17,18 A model validation based on
data resampling using 70% of randomly selected dataVolume 36 Number 6
M. Nakamura et al.was performed to assess the robustness of the model
that resulted from the process described above.
Treatment group (0.25 mg BID, 0.5 mg BID, or
1 mg BID of varenicline or placebo) was also considered
for inclusion in the initial set of predictors and in the
reduced model. However, because the treatment group
was not identiﬁed as a predictor during the model
building phase and neither affected the estimates in the
reduced models, treatment group was subsequently
dropped from inclusion for further consideration as a
predictor. All potential predictors were descriptively
summarized by status: smoking relapse (lapser or non-
lapser or relapser or nonrelapser). Odds ratios (ORs)
and 2-sided 95% CIs were calculated for identiﬁed
predictors. Time to lapse or time to relapse was assessed
using Kaplan-Meier plots.19 Statistical hypotheses were
not tested because of the anticipated small sample sizes.RESULTS
Participant Characteristics
The disposition of the participants used in this
subgroup analysis is shown in Figure 1. A total of 619
individuals were enrolled and randomized to receive
varenicline (0.25 mg BID, 0.5 mg BID, or 1 mg BID)
or placebo, and 618 participants received either
varenicline or placebo in the original clinical trial5;
577 (93.4%) completed treatment, and 510 (82.5%)619 Individuals
1 Not treated
153 Randomized to
varenicline 0.25 mg BID
128 Individuals  
with TDS ≥5
70 Individuals 
achieved Week
 9–12 CA
71 Individuals 
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failed Week
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156 Randomized to
varenicline 0.5 mg BID
Figure 1. Disposition of the study participants inclu
abstinence; TDS ¼ Tobacco Dependence Scre
June 2014completed the study. Most (approximately 75%) were
male, with a mean (SD) BMI of 23.0 (3.0) kg/m2. A
total of 515 participants had a score of Z5 on the
TDS. In total, 277 participants quit smoking
continuously for 4 weeks from weeks 9 to 12 of the
study and were included in this subgroup analysis.
Twelve participants discontinued the study in the
nontreatment follow-up period (8 because of adverse
events, 1 because of death [trafﬁc incident unrelated to
treatment], and 3 because of other reasons [no regular
follow-up hospital visits]). These individuals were
classiﬁed as lapsers or relapsers.Predictors of Lapse or Relapse
A summary of potential predictors by lapse and
relapse status is presented in Table I. Nonlapsers and
nonrelapsers were generally older and had a longer
maximum CA compared with lapsers and relapsers.
Maximum CA and age were identiﬁed as predictors of
both lapse and relapse. In addition, MNWS score for
urge to smoke and having made Z1 serious quit
attempt were identiﬁed as predictors of relapse (Table II).
When analyzed as categorical variables, shorter
maximum CA and younger age at quit attempt were
identiﬁed as being associated with increased risk of
lapse and relapse (Table III). In addition, higher
MNWS urge to smoke score was associated with enrolled
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Table I. Predictors of lapse and relapse: descriptive statistics by status
Potential Predictor
Lapse Relapse
Lapsers
(n ¼ 130)
Nonlapsers
(n ¼ 147)
Relapsers
(n ¼ 113)
Nonrelapsers
(n ¼ 164)
Demographic characteristics
Age, mean (SD), y 38.0 (12.2) 44.4 (12.0) 38.0 (12.3) 43.8 (12.0)
Male, No. (%) 95 (73.1) 114 (77.6) 82 (72.6) 127 (77.4)
Body mass index, mean (SD), kg/m2 23.2 (3.0) 23.2 (3.0) 23.3 (3.0) 23.1 (3.0)
Smoking
Age at onset of smoking, mean (SD), y 18.7 (3.1) 18.6 (2.4) 18.7 (2.8) 18.7 (2.8)
Length of smoking, mean (SD), y 18.9 (11.3) 25.3 (11.5) 18.9 (11.4) 24.6 (11.6)
Cigarettes per day in the past month, mean (SD) 22.8 (7.8) 23.3 (9.6) 22.9 (7.9) 23.2 (9.4)
Longest abstinence in previous year, No. (%)
0 days 90 (69.2) 121 (82.3) 77 (68.1) 134 (81.7)
1–30 days 37 (28.5) 23 (15.6) 33 (29.2) 27 (16.5)
430 days 3 (2.3) 3 (2.0) 3 (2.7) 3 (1.8)
Lives with a smoker, No. (%) 41 (31.5) 54 (36.7) 38 (33.6) 57 (34.8)
Frequent contact with smoker, No. (%) 120 (92.3) 131 (89.1) 104 (92.0) 147 (89.6)
Made Z1 serious quit attempt, No. (%) 98 (75.4) 93 (63.3) 89 (78.8) 102 (62.2)
Pack-years, mean (SD) 23.0 (18.0) 30.6 (21.8) 23.1 (18.0) 29.8 (21.6)
FTND score, mean (SD) 5.2 (2.0) 5.3 (2.1) 5.3 (2.0) 5.3 (2.0)
Baseline cotinine, mean (SD), ng/mL 261.0 (160.9) 249.9 (155.9) 262.5 (157.7) 250.1 (158.6)
Baseline weekly alcohol intake, mean (SD), U 18.8 (31.3) 16.7 (25.9) 19.0 (31.8) 16.8 (26.0)
MNWS and length of abstinence during treatment
phase
MNWS,* mean (SD)
Negative affect 0.1 (0.3) 0.1 (0.3) 0.2 (0.4) 0.1 (0.3)
Insomnia 0.4 (0.8) 0.3 (0.6) 0.4 (0.8) 0.3 (0.6)
Urge to smoke 0.5 (0.8) 0.4 (0.7) 0.6 (0.8) 0.4 (0.6)
Restlessness 0.1 (0.4) 0.1 (0.3) 0.1 (0.5) 0.1 (0.3)
Increased appetite 1.1 (1.2) 1.1 (1.3) 1.1 (1.3) 1.1 (1.3)
Quit pattern (immediate), No. (%) 51 (39.2) 85 (57.8) 42 (37.2) 94 (57.3)
Maximum CA,† mean (SD), wk 8.7 (2.5) 9.9 (1.7) 8.7 (2.5) 9.8 (1.8)
CA ¼ continuous abstinence; FTND ¼ Fagerström Test for Nicotine Dependence; MNWS ¼ Minnesota Nicotine
Withdrawal Scale.
*At week 12.
†Maximum CA during treatment phase.
Clinical Therapeuticsincreased risk of relapse (Table III). Table III details
the ORs generated by analysis using predictors as
categorical values. For participants with a maximum
CA of 4 to 6 weeks versus those with a maximum CA
of 10 to 11 weeks, the ORs for lapse and relapse were
4.649 (95% CI, 2.071–10.434) and 3.337 (95% CI,
1.538–7.239), respectively. In participants aged 21–34922years versus those aged 47–72 years, the ORs for lapse
and relapse were 3.453 (95% CI 1.851, 6.441) and
3.442 (95% CI 1.795, 6.597), respectively. Similarly,
those with a MNWS urge to smoke score of 2 to 4 had
an OR for relapse of 3.175 (95% CI, 1.166–8.644)
compared with those with a score of 0. Individuals
having made Z1 serious quit attempt versus noVolume 36 Number 6
Table II. Identified predictors of lapse and relapse using a logistic regression model.
Identified predictor* Odds ratio (95% CI) P value
Lapse
Maximum CA 0.762 (0.673–0.863) o0.0001
Age 0.958 (0.938–0.978) o0.0001
Relapse
Maximum CA 0.786 (0.696–0.887) o0.0001
Age 0.959 (0.938–0.981) 0.0002
MNWS urge to smoke 1.798 (1.241–2.604) 0.0019
Made Z1 serious quit attempt 2.278 (1.262–4.113) 0.0063
CA ¼ continuous abstinence; MNWS ¼ Minnesota Nicotine Withdrawal Scale.
*All predictors were continuous variables.
M. Nakamura et al.serious quit attempt had an OR for relapse of 2.108
(95% CI, 1.168–3.805). Figure 2 presents these results
as Kaplan-Meier plots. The Kaplan-Meier plots reveal
that individuals with high-risk predictors tend to
relapse to smoking earlier compared with those with
low-risk predictors.Table III. Identified predictors as categorical variables.
Identified predictor Lapser
Maximum CA, wk
4–6 4.649 (2.071–
7–9 2.342 (1.269–
10–11 —
Age, y
21–34 3.453 (1.851–
35–46 1.553 (0.828–
47–72 —
MNWS urge to smoke score
0 —
1 —
2–4 —
Made Z1 serious quit attempt
No —
Yes —
CA ¼ continuous abstinence; MNWS ¼ Minnesota Nicotine W
June 2014DISCUSSION
This post hoc study was conducted to identify pre-
dictors of smoking lapse and relapse in a population
of Japanese smokers treated with varenicline. It has
been reported that any smoking after the target quit
date is predictive of relapse.20,21 The results of thisOdds ratio (95% CI)
s Relapsers
10.434) 3.337 (1.538–7.239)
4.320) 2.474 (1.315–4.654)
—
6.441) 3.442 (1.795–6.597)
2.913) 1.845 (0.943–3.609)
—
—
1.975 (1.097–3.556)
3.175 (1.166–8.644)
—
2.108 (1.168–3.805)
ithdrawal Scale.
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Figure 2. Kaplan-Meier plots by maximum continuous abstinence (CA) (A), age (B), Minnesota Nicotine
Withdrawal Scale (MNWS) urge to smoke (C), and Z1 serious quit attempt (D).
Clinical Therapeuticsstudy revealed that when analyzed as categorical
variables, shorter maximum CA and younger age at
quit attempt were identiﬁed as being associated with
increased risk of lapse and relapse. In addition, higher
MNWS urge to smoke score was associated with an
increased risk of relapse. The risk of lapse for smokers
with a maximum CA of 4 to 6 weeks was 4.6 times
higher than with a maximum CA of 10 to 11 weeks.
These results are in agreement with those from a
pooled analysis of 2 registration studies for vareni-
cline, which revealed that maximum CA during the
treatment phase of the study and the longest period of
abstinence in the year before study entry were pre-
dictors of relapse.14 Hajek et al15 reported that the
later in the 12-week treatment period with varenicline924smokers obtained abstinence, the less likely they were
to remain abstinent at 1 year.
Individuals whose maximum CA was 4 to 6 weeks
started their CA nearer the end of the treatment phase
than those whose maximum CA was 10 to 11 weeks.
To prevent relapse, longer-term treatment after the
initial quit date would be required. Tonstad et al13
reported that the use of 12 weeks of maintenance
therapy with varenicline in smokers who achieved
abstinence for at least 7 consecutive days at the end of
standard varenicline treatment was associated with
signiﬁcantly improved quit rates compared with
placebo. Hajek et al15 reported that extended
treatment with varenicline prevented relapse in late
quitters (OR, 1.7; 95% CI, 1.2–2.4; P ¼ 0.0015) butVolume 36 Number 6
M. Nakamura et al.not in early quitters (OR, 1.1; 95% CI, 0.8–1.5; P ¼
0.6995). They also concluded that smokers should
have the best chance of successfully quitting if they
took varenicline for the full 12-week treatment period
while they are abstinent because this would permit
sufﬁcient time for neuroadaptation. Another pooled
analysis of the 2 varenicline registration studies in
which smokers received varenicline, bupropion sus-
tained release, or placebo2,3 revealed a positive corre-
lation between adherence to treatment and tobacco
abstinence.22 The authors reported that age, number
of cigarettes smoked per day, and week 2 abstinence
were signiﬁcant predictors of adherence for all
treatment groups. Our study also found that
smokers aged 21 to 34 years were more likely to
relapse compared with older smokers. These results
are in agreement with a number of other studies
reporting that older age is linked to a positive
cessation outcome.23–25
To our knowledge, this is the ﬁrst analysis to
identify predictors of smoking lapse and relapse in
Japanese smokers. This study investigated predictors
not only for lapse to smoking but also for relapse.
Maximum CA and age were identiﬁed as predictors of
both lapse and relapse; however, MNWS urge to
smoke score and having made Z1 serious quit
attempt were not identiﬁed as predictors of lapse.
Lapse was deﬁned as a break in abstinence, whether
or not it led to a full relapse. However, if the lapse
occurred for47 days during the follow-up period (ie,
280 days), the event was classiﬁed as a relapse. In this
study, 113 of 130 patients (86.9%) who lapsed also
relapsed. Therefore, it is not surprising to identify the
same predictors of lapse and relapse. However, urge to
smoke and Z1 serious quit attempt were identiﬁed as
predictors of relapse but not of lapse.
Several studies have examined the association be-
tween lapse and relapse and the urge to smoke. For
example, West et al26 found that smokers who had
frequent urges to smoke were likely to relapse in the
short term. Killen et al27 found that postquit craving was
signiﬁcantly associated with abstinence at the 2-month
follow-up and the intensity of craving was associated
with the time to relapse. Swan et al28 revealed that
craving was a robust predictor of relapse and a higher
level of craving was associated with a shorter time to
relapse. Brown et al29 reported that relapsers who had
never sustained any previous quit attempt for 424
hours tended to feel a greater urge to smoke comparedJune 2014with those who had sustained a quit attempt lasting for
Z3 months.
The results of this study for the urge to smoke are
consistent with previous studies. Reducing the urge to
smoke at the beginning of smoking cessation is
important to achieve long-term cessation. Recently,
Foulds et al30 reported the results of the effects of
varenicline on nicotine withdrawal symptoms from a
pooled analysis of 8 randomized, placebo-controlled
clinical trials of varenicline. The urge to smoke was
lower for varenicline than placebo.
The effect of the past quit attempt on lapse or
relapse has found conﬂicting results in earlier studies.
These different results may be related to the character-
istics of the participants (ie, all current smokers or quit
attempters only) and the deﬁnition of a past quit
attempt used in the various analyses. For example,
Hagimoto et al31 found that one of the predictors of
achieving abstinence successfully in a general Japanese
population was never having tried to quit before. In
both this study and the study by Hagimoto et al,31 the
study populations were limited to smokers who had
made a quit attempt during the follow-up period (quit
attempters). Hyland et al32 investigated predictors of
smoking cessation in quit attempters and all current
smokers. They found that a past quit attempt was not
a signiﬁcant predictor in quit attempters, whereas it
was negatively associated with smoking abstinence in
all current smokers, including quit attempters. In
contrast, Hymowitz et al23 found that a past quit
attempt was a positive predictor of quitting success,
but this was in an analysis of current smokers (ie,
using the different populations from the previous 2
studies and this study).
With regard to the inconsistent effects of a past quit
attempt on the results from this study and those of
Hagimoto et al31 and Hyland et al,32 it should be taken
into consideration that the deﬁnition of a past quit
attempt was different among the various studies. A past
quit attempt during a lifetime was deﬁned in the
present study and in the study by Hagimoto et al,31
whereas in the study by Hyland et al,32 a past quit
attempt was deﬁned as being during the previous year.
Several other studies have also reported that a past
quit attempt was positively associated with making a
further quit attempt.33–35 However, a past quit
attempt was also negatively associated with making
a further quit attempt in the study by Hyland et al.32
They reported that short previous past attempts925
Clinical Therapeutics(o1 week) were associated with reduced success,
whereas longer attempts (Z6 months) were
associated with increased success compared with no
previous attempt. These short failure attempts close to
the start of the study might have caused the smokers
to lose their conﬁdence, which reduced their
likelihood of a further quit attempt. As Hagimoto
et al31 pointed out, high motivation and past quit
attempts were considered to be expressions of the
smokers’ eagerness to quit smoking. A past quit
attempt was also a marker of unknown attributes or
circumstances, which made it hard to quit smoking
because it indicated that the smokers did not succeed
in quitting smoking despite their eagerness to stop.
The present study used a subgroup of patients (n ¼
277) from an earlier clinical trial.5 As a result, the
participants may have been subject to bias, and the
sample size was small. Therefore, further studies will
be required to conﬁrm these results. Furthermore, the
numbers of lapsers but not relapsers was very small (n
¼ 17). Additional analyses might be able to identify
more clearly the number of pure lapsers and the effect
of the urge to smoke and past serious quit attempt on
smoking relapse.
CONCLUSION
The results of this analysis suggest that shorter
maximum CA and younger age at quit attempt were
associated with increased risk of lapse and relapse.
Higher MNWS urge to smoke score was also asso-
ciated with an increased risk of relapse. A longer
treatment duration with varenicline after the initial
quit date could help prevent these relapses to smoking.
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